CYX.V - Calyx Ventures Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.045
0.000 (0.00%)
At close: 3:15PM EST
Stock chart is not supported by your current browser
Previous Close0.045
Open0.045
Bid0.045 x 0
Ask0.050 x 0
Day's Range0.045 - 0.045
52 Week Range0.040 - 0.420
Volume141,500
Avg. Volume261,768
Market Cap4.265M
Beta (3Y Monthly)2.23
PE Ratio (TTM)N/A
EPS (TTM)-0.021
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Simply Wall St.11 days ago

    Does Calyx Ventures Inc (CVE:CYX) Have A High Beta?

    If you’re interested in Calyx Ventures Inc (CVE:CYX), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could Read More...

  • GlobeNewswirelast month

    Calyx Announces Software Licensing Agreement

    Calyx Ventures Inc. (CYX.V) (“Calyx” or the “Company”) is pleased to announce that its wholly owned subsidiary Cannigistics Agri-Solutions Corp. “Cannigistics” has licensed and deployed its proprietary B2B framework “IndustryCast” to CBCB Beef Inc. CBCB Beef Inc. is a primary service provider for BC raised cattle that is “purchased and finished” within the borders of British Columbia. British Columbia has some of the highest standards for beef raised without the use of hormones or steroids and CBCB Beef Inc. has created BC Beefnet to be the premiere platform to connect the “rancher to restaurant”.

  • GlobeNewswirelast month

    Calyx Announces Option Grant

    VANCOUVER, British Columbia, Oct. 09, 2018 -- Calyx Ventures Inc. (TSXV: CYX) (“Calyx” or the “Company”) is pleased to announce that it will grant 2,500,000 incentive stock.

  • ACCESSWIRE8 months ago

    Today’s Research Reports on Concordia International, GeneNews, Medicure and Calyx Ventures

    NEW YORK, NY / ACCESSWIRE / March 5, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • ACCESSWIRE10 months ago

    Today’s Research Reports on Emblem Corp., Cronos Group Inc., Calyx Bio-Ventures Inc. and Theralase Technologies Inc.

    NEW YORK, NY / ACCESSWIRE / January 11, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...